Use of Warfarin After the First Trimester in Pregnant Women With APS

Launched by MOHAMED SAYED ABDELHAFEZ · Nov 25, 2014

Keywords

ClinConnect Summary

This clinical trial is studying how safe and effective it is to switch from a medication called low molecular weight heparin (LMWH) to warfarin, an oral blood thinner, for pregnant women with antiphospholipid syndrome (APS) after the first trimester. APS is a condition that can lead to recurrent miscarriages and complications in pregnancy. The trial aims to see if this change in medication during pregnancy can still help keep mothers and their babies healthy.

To be eligible for this study, participants need to be pregnant women who have been diagnosed with APS based on specific criteria. They should also weigh between 50 and 90 kilograms during early pregnancy. However, women with systemic lupus erythematosus (SLE), active blood clotting issues, or a history of blood clots are not allowed to participate. If you join the trial, you will receive close monitoring and support from the research team as they gather important information about the effects of these medications during your pregnancy.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Pregnant women with APS diagnosed according to the revised classification criteria for APS in 2006 in Sydney, Australia
• • Early pregnancy body weight is 50-90 Kg
• Exclusion Criteria:
• • Women with systemic lupus erythematosus (SLE)
• • Women with active thromboembolic disorders
• • Women with history of previous thromboembolic disorders